CXCL9 and facioscapulohumeral muscular dystrophy: To further evaluate if CXCL9 and eotaxin are candidate FSHD circulating biomarkers, we quantified the levels of these chemoattractants in the sera of FSHD patients and healthy subjects through ELISA.